Humacyte adds Scott Coward to board, names him to audit committee

By Public Technologies
  • Humacyte added Scott Coward and Paul Kuznik to its board as it expands the Symvess launch and prepares an ATEV dialysis-access launch.
  • Coward was EVP, chief legal officer, chief administrative officer, secretary at Exact Sciences from 2015-2022; later served on its board through March 2026.
  • He joined K&L Gates in July 2026; appointed to Humacyte’s audit committee.
  • Kuznik was CEO and a director at Bolton Medical from 2015-2018; later led Terumo Aortic’s US and North America units through 2023.
  • He was appointed to Humacyte’s commercial committee.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834407) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk